2620 related articles for article (PubMed ID: 7600565)
1. An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models.
Rosenblum MG; Cheung L; Mujoo K; Murray JL
Cancer Immunol Immunother; 1995 May; 40(5):322-8. PubMed ID: 7600565
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Mujoo K; Cheung L; Murray JL; Rosenblum MG
Cancer Immunol Immunother; 1995 May; 40(5):339-45. PubMed ID: 7600567
[TBL] [Abstract][Full Text] [Related]
3. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
4. Effects of monoclonal antibody, recombinant interferon-gamma, and tumor necrosis factor-alpha in the treatment of human melanoma xenografts.
Gridley DS; Slater JM; Stickney DR
J Biol Response Mod; 1989 Dec; 8(6):593-602. PubMed ID: 2513378
[TBL] [Abstract][Full Text] [Related]
5. Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cells.
Rosenblum MG; Cheung L; Kim SK; Mujoo K; Donato NJ; Murray JL
Cancer Immunol Immunother; 1996 Feb; 42(2):115-21. PubMed ID: 8620520
[TBL] [Abstract][Full Text] [Related]
6. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
[TBL] [Abstract][Full Text] [Related]
7. Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance.
Rosenblum MG; Cheung L; Murray JL; Bartholomew R
Cancer Commun; 1991 Jan; 3(1):21-7. PubMed ID: 1989645
[TBL] [Abstract][Full Text] [Related]
8. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Rosenblum MG; Murray JL; Cheung L; Rifkin R; Salmon S; Bartholomew R
Mol Biother; 1991 Mar; 3(1):6-13. PubMed ID: 1906286
[TBL] [Abstract][Full Text] [Related]
9. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
11. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody.
Pietersz GA; Toohey B; McKenzie IF
J Drug Target; 1998; 5(2):109-20. PubMed ID: 9588867
[TBL] [Abstract][Full Text] [Related]
13. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
14. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice.
Benhar I; Pastan I
Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075
[TBL] [Abstract][Full Text] [Related]
15. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319
[TBL] [Abstract][Full Text] [Related]
16. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2.
Yamamoto A; Sawada T; Yamashita Y; Nishihara T; Ho JJ; Kim Y; Chung KH
Oncol Rep; 1999; 6(1):179-84. PubMed ID: 9864424
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.
Friedman PN; Chace DF; Trail PA; Siegall CB
J Immunol; 1993 Apr; 150(7):3054-61. PubMed ID: 8454873
[TBL] [Abstract][Full Text] [Related]
19. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
